[go: up one dir, main page]

AR101856A1 - TREATMENT OF PROGRESSIVE OSIFYING FIBRODISPLASIA - Google Patents

TREATMENT OF PROGRESSIVE OSIFYING FIBRODISPLASIA

Info

Publication number
AR101856A1
AR101856A1 ARP150102922A ARP150102922A AR101856A1 AR 101856 A1 AR101856 A1 AR 101856A1 AR P150102922 A ARP150102922 A AR P150102922A AR P150102922 A ARP150102922 A AR P150102922A AR 101856 A1 AR101856 A1 AR 101856A1
Authority
AR
Argentina
Prior art keywords
acvr2a
acvr1
acvr2b
type
osifying
Prior art date
Application number
ARP150102922A
Other languages
Spanish (es)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of AR101856A1 publication Critical patent/AR101856A1/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Métodos para tratar la fibrodisplasia osificante progresiva (FOP). Tales métodos implican la administración a un sujeto que tiene FOP un régimen de antagonista del receptor de la activina tipo 2A (ACVR2A) y/o un receptor de la activina tipo 2B (ACVR2B) o un antagonista del receptor de la activina tipo 1 (ACVR1). Los antagonistas incluyen las proteínas de fusión de uno o más dominios extracelulares (ECD) de ACVR2A, ACVR2B y/o ACVR1 y el dominio Fc de una cadena pesada de inmunoglobulina, y anticuerpos contra ACVR2A, ACVR2B, ACVR1 o activina A.Methods to treat progressive ossifying fibrodysplasia (FOP). Such methods involve administration to a subject having FOP a type 2A activin receptor antagonist (ACVR2A) and / or a type 2B activin receptor (ACVR2B) or a type 1 activin receptor antagonist (ACVR1) ). Antagonists include the fusion proteins of one or more extracellular domains (ECD) of ACVR2A, ACVR2B and / or ACVR1 and the Fc domain of an immunoglobulin heavy chain, and antibodies against ACVR2A, ACVR2B, ACVR1 or activin A.

ARP150102922A 2014-09-12 2015-09-14 TREATMENT OF PROGRESSIVE OSIFYING FIBRODISPLASIA AR101856A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462049869P 2014-09-12 2014-09-12

Publications (1)

Publication Number Publication Date
AR101856A1 true AR101856A1 (en) 2017-01-18

Family

ID=58698596

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150102922A AR101856A1 (en) 2014-09-12 2015-09-14 TREATMENT OF PROGRESSIVE OSIFYING FIBRODISPLASIA

Country Status (2)

Country Link
AR (1) AR101856A1 (en)
MA (1) MA40115A1 (en)

Also Published As

Publication number Publication date
MA40115A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
CL2017000603A1 (en) Treatment of progressive ossifying fibrodysplasia
MX2017007491A (en) Blood brain barrier receptor antibodies and methods of use.
PH12017501521A1 (en) Anti-dll3 chimeric antigen receptors and methods of use
CO2017000506A2 (en) Chimeric cll-1 antigen receptor
PH12017501039A1 (en) Antibodies targeting g-protein coupled receptor and methods of use
CO2017001573A2 (en) Chimeric anti-cd123 antigen receptor
MX2022007894A (en) CONDITIONALLY ACTIVE CHIMERIC ANTIGEN RECEPTORS FOR MODIFIED T CELLS.
MX2018000278A (en) THERAPY OF CHEMICAL RECEPTORS OF IMMUNE CONTROL POINTS.
CO2017000507A2 (en) Chimeric bcma antigen receptor
CO2017000510A2 (en) Car constructs
EA201791310A1 (en) CHEMERIC ANTIGEN RECEPTORS TO BCMA
UY36068A (en) TGF-ß INHIBITORS AND METHODS OF USE
EA201790834A1 (en) ANTIBODY MOLECULES TO PD-L1 AND THEIR APPLICATION
CR20160500A (en) ANTI-OX40 ANTIBODIES AND METHODS OF USE
MY193661A (en) Anti-tim3 antibodies and methods of use
UY36021A (en) FC MULTIMÈRIC PROTEINS
UY36471A (en) ANTIBODIES AGAINST THE IMMUNORRECEPTOR (TIGIT) OF T LYMPHOCYTES WITH IG DOMAINS AND REASONS FOR INHIBITION OF THE TYMOSINE-BASED IMMUNORRECEPTOR (ITIM)
CL2018001722A1 (en) New anti-mfi2 antibodies and methods of use (divisional application 201700506)
PH12017500825A1 (en) Anti-cldn chimeric antigen receptors and methods of use
EA201790984A1 (en) ANTI-CD79B ANTIBODIES AND METHODS OF THEIR APPLICATION
MX2016009954A (en) Antibodies against the muc1-c/extracellular domain (muc1-c/ecd).
BR112016020377A2 (en) multimeric fc proteins
EA201691610A1 (en) ANTI-JAGGED1 ANTIBODIES AND METHODS OF APPLICATION
EA201790356A1 (en) Methyl and trifluoromethyl substituted PYRROPYRIDINE MODULATORS RORC2 AND METHODS OF THEIR APPLICATION
EA201790314A1 (en) NEW ANTIBODIES DIRECTED TO FC-GAMMA-RECEPTOR IIB AND FC-EPSILON-RECEPTOR

Legal Events

Date Code Title Description
FB Suspension of granting procedure